| 0.5399 -0 (-0.02%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.66 | 1-year : | 0.77 |
| Resists | First : | 0.56 | Second : | 0.66 |
| Pivot price | 0.51  |
|||
| Supports | First : | 0.43 | Second : | 0.34 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.48 |
| MA(100) : | 0.7  |
MA(250) : | 0.73 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 85.8 |
D(3) : | 88.2 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 1.2 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed below upper band by 31.0%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.55 - 0.55 | 0.55 - 0.56 |
| Low: | 0.51 - 0.51 | 0.51 - 0.51 |
| Close: | 0.53 - 0.54 | 0.54 - 0.54 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Fri, 26 Jul 2024
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Drop in Short Interest - Defense World
Mon, 22 Jul 2024
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. - StockTitan
Wed, 10 Jul 2024
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB - StockTitan
Tue, 09 Jul 2024
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 2% - Defense World
Fri, 28 Jun 2024
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Tue, 04 Jun 2024
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 4.022e+007 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 1,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.414e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 235.8 % |
| Return on Equity (ttm) | -42.9 % |
| Qtrly Rev. Growth | 1.379e+007 % |
| Gross Profit (p.s.) | -29.14 |
| Sales Per Share | -62.92 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.49 |
| Dividend | 0 |
| Forward Dividend | 2.16e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|